How Chick-fil-A creates meaningful impact in NYC
Chick-fil-A restaurants across New York, New Jersey and Connecticut are creating impactful change in their neighborhoods.
Here's why: Chick-fil-A's corporate social responsibility efforts reflect the company's commitment to being responsible stewards and positively influencing the communities they serve.
The company focuses on creating moments of care for people, for communities, through their food and for the planet.
How it's done: Local Chick-fil-A Owner-Operators in the Tri-State are leading the way with multiple initiatives, including…
🎓 Sending kids to college with scholarships
Each year, Chick-fil-A restaurant team members are offered the opportunity to apply for college scholarships through the Chick-fil-A Remarkable Futures™ scholarship program.
The local impact: Since 1975, 1,500+ scholarships have been awarded across NYC for a total of over $3 million in scholarships.
🍗 Donating surplus food to neighbors in need
The Chick-fil-A Shared Table® program empowers local Owner-Operators to donate surplus food at the end of each day to charitable organizations in their community.
Key numbers: Across all five boroughs, more than 196,000 meals have been created through Chick-fil-A Shared Table.
Local Owner-Operator Senay Mekonen of Chick-fil-A Marble Hill has donated 8,700 meals to Love Kitchen, a Bronx-area nonprofit.
Brandon Hurst, the local Owner-Operator of two Chick-fil-A restaurants in Brooklyn, has collectively helped create 55,000 meals for those in need in partnership with Prosperity in the Hood and Next Step Community Church.
Local Owner-Operator Jared Caldwell of Chick-fil-A 79th & 2nd and Chick-fil-A 1536 3rd Ave has collectively donated over 5,000 meals to two Manhattan nonprofits: Gotham Food Pantry and the Jamaican Women's Employment Shelter.
❤️ Making a positive impact on local youth
Tri-State area local owner-operators give back to youth, including sponsoring Chick-fil-A Leader Academy in local high schools, which offers seed funding in the form of microgrants to help support participating schools' community impact projects.
Some examples: Many local owner-operators are also involved in local boards and nonprofits.
Roosevelt Board, the local owner-operator at Chick-fil-A Staten Island Mall, was one of seven business owners honored by the borough. He's involved in the Chamber's Young Entrepreneurs Academy, an innovative after-school program that helps high school students launch their own business. Board acts as a mentor, guest speaker, sponsor and a field trip host.
Marc Thompson, the local owner-operator at Chick-fil-A Five Towns, hosts fundraisers for local schools, invites students to the restaurant for Meet the Operator days to learn about the restaurant business and donates meals to students participating in local events focused on STEAM, leadership development and entrepreneurship.
♻️ Recycling used cooking oil to help the environment
Chick-fil-A partners with DAR PRO Solutions for an innovative oil-reclamation program.
How it works: All locally owned and operated Chick-fil-A restaurants in NYC recycle used cooking oil from their restaurants to create renewable diesel.
To date, Chick-fil-A restaurants across the country have generated more than two million gallons of renewable diesel.
💸 Funding for nonprofits through grants
The True Inspiration Awards® program celebrates and supports nonprofit organizations making an impact in their local communities with annual grants.
The positive news: In 2024, Harlem Grown received a $200,000 True Inspiration Awards grant. The youth education program addresses the hunger facing 24% of low-income children and their families in New York City's Harlem community.
With the funding from Chick-fil-A, Harlem Grown plans to enhance its newly launched Independent Afterschool Program.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors
The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 patients with stable disease. Based on this promising data, BioInvent plans to initiate Phase 2a expansion cohorts to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC) or uveal melanoma, in the front line in combination with KEYTRUDA® (pembrolizumab). Patient enrollment is expected to begin H2 2025. LUND, SE / / June 11, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated, positive Phase 1 data of intravenous (IV) and subcutaneous (SC) BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with solid tumors. Based on the encouraging data, the company intends to expand its investigation of BI-1206 SC in combination with pembrolizumab in earlier lines of treatment, by initiating a Phase 2a study arm with focus on first-line patients with advanced or metastatic NSCLC and uveal melanoma. The Phase 2a study is planned to be initiated during H2 2025. The updated Phase 1 data in heavily pre-treated patients - including several lines of IO agents - show encouraging clinical activity of the combination, with one patient with metastatic cutaneous melanoma experiencing a complete response (CR), one patient with metastatic uveal melanoma achieving a long-lasting partial response (PR) and 11 patients experiencing stable disease (SD) out of a total of 36 evaluable patients. The product was well-tolerated, enabling continued dose expansion exploring the use of higher dose levels. The trial is part of BioInvent's strategy to transition from IV dosing to SC formulation for BI-1206 allowing slower systemic entry and prolonged time on target to enhance the products therapeutic impact and improve safety and tolerability of the combination. The Phase 1 data in solid tumors corroborate preclinical findings that BI-1206 significantly enhances the effect of anti-PD-1. Based on this evidence, MSD and BioInvent have agreed to further investigate the synergies between BI-1206 and pembrolizumab in earlier lines of treatment. The upcoming Phase 2a study of BI-1206 in combination with pembrolizumab is planned to be performed in treatment-naïve patients with NSCLC and uveal melanoma. "We are highly encouraged by the clinical responses emerging from our solid tumor program which support the broad utility of combining subcutaneous BI-1206 with pembrolizumab in a range of solid tumors," said Martin Welschof, Chief Executive Officer of BioInvent. "The strong signals we have observed in heavily pre-treated patients support the idea that BI-1206 could be used to improve the activity of pembrolizumab across different tumor types, and we therefore look forward to initiating our Phase 2a study in the high unmet medical need of non-small cell lung cancer." KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. ###About NSCLC and combination treatment with targeting FcyRIIBNSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. While checkpoint inhibitors are widely accepted and can produce durable responses in NSCLC, the overall response rate remains low, rarely exceeding 25%. A common resistance mechanism in cancer is the binding and degradation of therapeutic antibodies against PD-1 such as pembrolizumab by FcγRIIB expressing immune cells. Therefore, based on preclinical and early clinical data, the company believes that resistance or lack of response to anti-PD-1 treatment may be overcome by FcγRIIB blockade in particular in subjects who have never been exposed to anti PD-1 agents. About BI-1206BI-1206 is one of BioInvent's lead drug candidates and is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab. The drug candidate is evaluated in two separate clinical programs, one for the treatment of solid tumors and one for the treatment of non-Hodgkin's lymphoma (NHL, a type of blood cancer). BI-1206 in solid tumorsClinical Phase 1/2a study with BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with solid tumors (NCT04219254) is ongoing. The concluded Phase 1 dose escalation study in heavily pre-treated patients shows encouraging clinical activity of the combination, including one CR in metastatic melanoma, one PR in uveal melanoma and 11 patients experiencing SD out of a total of 36 evaluable patients. The product was well-tolerated, enabling continued dose expansion exploring the use of higher dose levels. For further details, please refer to the ASCO 2024 poster on the company web site: Out of the patients with stable disease as best response, one patient with long-lasting metastatic melanoma, who had previously progressed on nivolumab treatment, remained a stable disease throughout the two-year study duration with BI-1206 and pembrolizumab. The planned Phase 2a study of BI-1206 in combination with pembrolizumab for treatment-naïve patients with NSCLC and uveal melanoma consists of two parts: a signal seeking phase and a dose optimization phase. In the first signal seeking phase, up to 30 NSCLC and 12 uveal melanoma patients will receive fixed doses of BI-1206 and pembrolizumab every 21 days for three treatment cycles. Patients showing clinical benefit by Week 9 can continue therapy for up to 32 additional cycles, while those with disease progression will not proceed further. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. Attachments BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors SOURCE: BioInvent International View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Hamilton Spectator
41 minutes ago
- Hamilton Spectator
WSP to acquire Ricardo, a global strategic and engineering consultancy firm
MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) — WSP Global Inc. (TSX: WSP) ('WSP' or the 'Corporation'), one of the world's leading professional services firms, announces that it has reached agreements to acquire the entire issued and to be issued share capital of Ricardo plc ('Ricardo') for 430 pence (the 'Offer Price') per share (the 'Acquisition'). This Acquisition underscores WSP's commitment to expanding its footprint in high-growth sectors worldwide. Headquartered in the United Kingdom, Ricardo is a global consulting firm delivering strategic, advisory, and engineering solutions that intersect the global transport, energy, and environment agendas. Operating in over 20 countries, Ricardo is home to approximately 2,700 experts based across Europe, Australia, North America, Asia, and the Middle East. Its activities are grouped under two main portfolios: Over the last few years, Ricardo has been reorienting its business to become a leading strategic and engineering consultancy firm, focused on its EE and Rail portfolio. Under WSP's ownership, Ricardo will continue its ongoing strategic review of the A&I and PP business units. While no firm decisions have been taken, the outcome of the strategic review is likely to result in a sale of the A&I and PP businesses at the appropriate time. This Acquisition represents an excellent opportunity for WSP to progress its 2025-2027 Global Strategic Action Plan and accelerate its expansion in targeted high-growth areas. Specialized and differentiated, Ricardo's value-added expertise in rail, air quality, water management, energy resilience, policy strategy, and advisory supplements and elevates WSP's offering in core market sectors. Geographically, Ricardo matches up well with WSP's existing footprint and further strengthens its presence in several key markets, including the UK, Australia, and the Netherlands. 'The proposed acquisition of Ricardo perfectly aligns with WSP's vision for sustainable, compounding growth and our clear ambitions to expand in advisory, energy transition, water solutions, and the rail sector over the next three years,' expressed Alexandre L'Heureux, President and CEO of WSP. 'We are poised to enhance our ability to deliver innovative solutions as we combine our global reach and resources with Ricardo's complementary expertise. Moreover, the shared entrepreneurial spirit and technical excellence between our teams position us to create further value for our clients. We look forward to welcoming Ricardo's talented professionals to WSP and seizing new opportunities with our broadened service offering.' The Acquisition reflects an enterprise value of approximately £363.1 million (approximately $670 million), which represents a multiple of 10.4x Ricardo's pre-IFRS 16 underlying EBITDA1 for the 12-month period ended December 31, 2024, based on Ricardo's continuing operations after the divestment of their defense business and including the full year contribution of their acquisition of E3A Advisory PTY Ltd. For further details regarding this announcement, readers are referred to the firm offer announcement in respect of the Acquisition (the 'Announcement') previously released in the United Kingdom on the date hereof in accordance with Rule 2.7 of the UK City Code on Takeovers and Mergers and which can be found on WSP's website at . This press release should be read in conjunction with, and is subject to, the full text of the Announcement. ACQUISITION AND TIMETABLE WSP has reached an agreement with the board of Ricardo on the terms of a recommended cash acquisition pursuant to which a wholly owned subsidiary of WSP will acquire the entire issued and to be issued share capital of Ricardo at the Offer Price, excluding a 19.9% interest in Ricardo which WSP will acquire from Science Group plc at the Offer Price on or around June 16, 2025 pursuant to a share purchase agreement dated as of the date hereof (the 'Scheme Acquisition'). WSP has also received undertakings from each of Ricardo's directors and some of its major shareholders in respect of a total number of shares representing in the aggregate approximately 45.1% of Ricardo's issued share capital on June 10, 2025, as well as a letter of intent from a shareholder in respect of a total number of shares representing approximately 3% of Ricardo's issued share capital on June 10, 2025, to vote in favor of the Scheme Acquisition at the Ricardo shareholder meetings to be convened in connection with the Scheme. It is intended that the Scheme Acquisition will be implemented by means of a Court-sanctioned scheme of arrangement (the 'Scheme') under Part 26 of the UK Companies Act 2006. The purpose of the Scheme is to provide for WSP to, indirectly, via a wholly-owned subsidiary, become the owner of the entire issued and to be issued share capital of Ricardo, other than the shares which WSP will have acquired from Science Group on or around June 16, 2025. Details of the proposed Scheme Acquisition will be sent to Ricardo shareholders within 28 days of the date of the Announcement (unless the Panel on Takeovers and Mergers under the U.K. City Code on Takeovers and Mergers agrees otherwise). Subject, amongst other things, to the satisfaction or waiver of the conditions, the approval of the Scheme by the Ricardo shareholders, the receipt of applicable regulatory approvals and the Court's sanction of the Scheme, it is expected that the Acquisition will be completed in Q4 2025. ACQUISITION FINANCING Concurrently with the announcement of the Acquisition, WSP has obtained a fully committed 'certain funds' £230 million term loan facility (the 'New Credit Facility') (approximately $425 million). The remaining portion of the cash consideration for the Acquisition will be financed through cash on hand and existing credit facilities. Royal Bank of Canada is acting as lead arranger and sole bookrunner with respect to the New Credit Facility. The New Credit Facility is designed to ensure compliance with the 'certain funds' requirements from the announcement of the Scheme Acquisition under the UK City Code on Takeovers and Mergers. FINANCIAL AND LEGAL ADVISORS RBC Capital Markets is acting as financial advisor to WSP on the Acquisition. Legal advice is being provided to WSP by Linklaters LLP internationally. FORWARD-LOOKING STATEMENTS In addition to disclosure of historical information, WSP may make or provide statements or information in this press release that are not based on historical or current facts and which are considered to be forward-looking information or forward-looking statements (collectively, 'forward-looking statements') under Canadian securities laws. These forward-looking statements relate to future events or future performance and reflect the expectations of management of WSP ('Management') regarding, without limitation, the growth, results of operations, performance and business prospects and opportunities of WSP or the trends affecting its industry. Forward-looking statements in this press release include, without limitation, statements about the pending Acquisition by WSP of Ricardo; the conditions precedent to the closing of the Scheme Acquisition; the expected closing date of the Scheme Acquisition; the New Credit Facility; the acquisition of shares from Science Group plc and the timing thereof; the attractiveness of the Acquisition from a financial and strategic perspective; the result of the strategic review of the A&I and PP businesses and the likely outcome of a sale of those business units; other anticipated benefits of the Acquisition and their expected impact on WSP's delivery of its strategic plan and its long-term vision, future growth, results of operations, performance, business, prospects and opportunities, WSP's business outlook, objectives, development, plans, growth strategies and other strategic priorities, and WSP's leadership position in its markets; and statements relating to WSP's future growth, results of operations, performance business, prospects and opportunities. Forward-looking statements can typically be identified by terminology such as 'may', 'will', 'should', 'expect', 'plan', 'anticipate', 'believe', 'estimate', 'predict', 'forecast', 'project', 'intend', 'target', 'potential', 'continue' or the negative of these terms or terminology of a similar nature. Such forward-looking statements reflect current beliefs of Management and are based on certain factors and assumptions, which by their nature are subject to inherent risks and uncertainties. While WSP considers these factors and assumptions to be reasonable based on information available as at the date of this press release, actual events or results could differ materially from the results, predictions, forecasts, conclusions or projections expressed or implied in the forward-looking statements. Forward-looking statements made by WSP are based on a number of assumptions believed by WSP to be reasonable as at the date of this press release, including assumptions about the satisfaction of all closing conditions; the expected timing of completion of the Acquisition and the conditions precedent to the closing of the Scheme Acquisition (including the approval of the Scheme by the Ricardo shareholders, the receipt of applicable regulatory approvals and the Court's sanction of the Scheme); WSP's ability to retain and attract new business, achieve synergies and maintain market positions arising from successful integration plans relating to the Acquisition; WSP's ability to otherwise complete the integration of Ricardo within anticipated time periods and at expected cost levels; WSP's ability to attract and retain key employees in connection with the Acquisition; Management's estimates and expectations in relation to future economic and business conditions and other factors in relation to the Acquisition and resulting impact on growth and various other financial metrics; Management's expectations in relation to the future performance and economic conditions and other factors in relation to Ricardo; the realization of the expected strategic, financial and other benefits of the Acquisition in the timeframe anticipated; the accuracy and completeness of the information (including financial information) provided by Ricardo and publicly available information; the absence of significant undisclosed costs or liabilities associated with the Acquisition; WSP or Ricardo being adversely impacted during the pendency of the Acquisition; and other factors discussed or referred to in the 'Risk Factors' section of WSP's Management's Discussion and Analysis for the fourth quarter and year ended December 31, 2024 (the '2024 MD&A'), and WSP's Management's Discussion and Analysis for the three-month period ended March 29, 2025 (the 'Q1 2025 MD&A' and together with the 2024 MD&A, the 'MD&As') and filed on SEDAR+ at . If any of these assumptions prove to be inaccurate, WSP's actual results could differ materially from those expressed or implied in forward-looking statements. WSP's forward-looking statements are expressly qualified in their entirety by this cautionary statement. For additional information on this cautionary note regarding forward-looking statements as well as a description of the relevant assumptions and risk factors likely to affect WSP's actual or projected results, reference is made to the MD&As, which are available on SEDAR+ at . The forward-looking statements contained in this press release are made as of the date hereof and except as required under applicable securities laws, WSP does not undertake to update or revise these forward-looking statements, whether written or verbal, that may be made from time to time by itself or on its behalf, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this press release are expressly qualified by these cautionary statements, as well as other risks detailed from time to time in reports filed by the Corporation with securities regulators or securities commissions or other documents that the Corporation makes public, which may cause events or results to differ materially from the results expressed or implied in any forward-looking statement. As such, there can be no assurance that actual results will be consistent with forward-looking statements. About WSP WSP is one of the world's leading professional services firms, uniting its engineering, advisory and science-based expertise to shape communities to advance humanity. From local beginnings to a globe-spanning presence today, WSP operates in over 50 countries and employs approximately 73,000 professionals, known as Visioneers. Together they pioneer solutions and deliver innovative projects in the transportation, infrastructure, environment, building, energy, water, and mining and metals sectors. WSP is publicly listed on the Toronto Stock Exchange (TSX:WSP). About Ricardo Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 110 years of engineering excellence and approximately 2,700 employees in more than 20 countries, Ricardo provides exceptional levels of expertise in delivering innovative cross-sector sustainable outcomes to support energy transition and environmental services, together with safe and smart mobility. Its global team of consultants, environmental specialists, engineers, and scientists support our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. All dollar figures in this press release are Canadian dollars unless otherwise indicated. Where financial information of Ricardo has been converted from British pounds sterling to Canadian dollars for purposes of comparison to and combination with, financial information of WSP, British pounds sterling have been converted to Canadian dollars at an exchange rate of $1.8462 Canadian dollars per £1.00. 1 Ricardo's pre-IFRS 16 underlying EBITDA means earnings before finance expense, income tax expense, depreciation, and amortization, and includes rent expense and the benefit of major restructuring programs, but excludes significant costs (such as acquisition-related expenditures, reorganization costs, and other specific adjusting items).
Yahoo
an hour ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
